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ABSTRACT
Amphetamine and cocaine has long been known as drug of abuse. These drugs
impart their physiological manifestations by regulating the reward circuitry of the brain
which is controlled primarily by the dopaminergic pathway where they control the release
of dopamine. It has been found that repeated cocaine administration changes histone
acetylation patterns at the promoter sequences of several important genes. Sirtuin proteins
are histone deactylases that regulate important biological functions have also been found
to be elevated in the nucleus accumbens after cocaine administration. Although there
have been several studies that have tried to elucidate the mode of action of amphetamine,
it is still not known whether the drug of abuse, induces heritable histone modifications at
affects each of the genes of the dopaminergic pathway by inducing changes at the
promoter regions of these genes. Therefore, in order to better understand the mechanism
of the action of amphetamine, the goal of the present study is to look into the effect of
amphetamine in stimulation of epigenetic changes by the induction of histone
modifications at the promoters of genes of the dopaminergic pathway. We chose
Caenorhabditis elegans (C. elegans) as our experimental model system for our study.
Dopamine is synthesized in eight sensory neurons (4 CEP, 2 ADE and 2 PDE) and
modulates locomotion, learning and egg laying activity. All the known dopaminergic
components involved in DA synthesis, vesicle storage, release and reuptake are highly
conserved between the worm and mammals.

xi

In order to identify the histone modifications that are affected by amphetamine
administration, immunoblot followed by mRNA expression was performed which
revealed that amphetamine indeed affects the expression of histone modifications. For,
gene specific investigation, chromatin immunoprecipitation was employed. Chromatin
immunoprecipitation revealed that amphetamine treatment down regulates the expression
of dat-1, the dopamine transporter and cat-1, vesicular monoamine transporter by
reducing the enrichment of tri-methylated H3K4. Amphetamine treatment also increases
the expression of cat-2, tyrosine hydroxylase by reducing the enrichment of trimethylated H3K27.Our results also showed that amphetamine treatment has no effect on
the expression of bas-1, the aromatic amino acid decarboxylase. We further confirmed
our results by mRNA expression. These results indicate the role of amphetamine in
inducing changes in the histone modifications, though further research is needed to
confirm the observations.
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Chapter 1
Introduction
The concept of Addiction
Addictive drugs have been in usage for thousands of years. For example, there has
been evidence that shows that clinical opium was considered as a “joy plant” in Sumeria
in 5000BC, where opium was generally used as opium vapors. The Chinese had the
concept of “recreational opium smoking” since early 1600s. The concept of addiction
(uncontrollable drug habit) was developed in 1822 by Thomas De Quincey in
“Confessions of an English Opium Eater” (1).
Addiction became rampant with the introduction of the hypodermic syringe
during the American Civil War, which increased the appeal for the usage of morphine
and opium. After morphine, came the use of cocaine. Cocaine was introduced by modern
chemists in the 19th century. Cocaine was used in the soft drink coca-cola in 1886. The
concept of cocaine as an addictive drug was raised in 1887 by an American physician.
Amphetamine
Amphetamine is a psychostimulant drug that has been used for the treatment of a
variety of disorders including Attention Deficit Hyperactivity disorder (ADHD), obesity,
brain injury and others because of its ability to release catecholamine(2).
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Evolution of Amphetamine as an abusive drug
Amphetamine has been in significant use since synthetic amphetamine was
invented in 1887 by a Romanian chemist, Lazar Edeleano. Since then chemists and
researchers have developed wide range of synthetic derivatives of Amphetamine.
Synthetic amphetamine was introduced commercially by Smith Kline and French, as an
inhaler form and marketed as ‘Benzedrine’, in the early 1930s for the treatment of
narcolepsy. Use of Amphetamine was rampant among various military personnel around
the world in order to promote alertness (3). Millions of tablets were supplied to various
military troops during the Second World War for increasing alertness. It was especially
common amongst the Air Force personnel.
As the usage of the drug increased, so did its abuse. Initial abuse of amphetamine
usage started among students in various universities followed by artists, musicians, the
armed forces, and truck drivers in order to increase alertness(3). Since then, amphetamine
abuse has increased in epidemic proportions in United States and around the world. As of
2000, the U.S Drug Enforcement Agency (D.E.A) has identified methamphetamine
(METH) as the most illicitly used controlled manufactured substance (3).
Abusive property of Amphetamine and the Effects
The additive potential of amphetamine was mentioned as early as 1937, although
the reasons behind it were obscure. It was only in the early 1960s, when the initial reports
of central nervous system neurotoxicity induced by amphetamines appeared, that
amphetamine was widely recognized as an addictive substance.
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The dependence on amphetamine arose from the fact that acute amphetamine
administration can cause a wide range of behavioral effects in a dose dependent manner,
including increased alertness, anorexia, hyperactivity and emotional effects including a
state of elation and euphoria (3).
Dopamine
Dopamine, a member of the catecholamine family, is an important
neurotransmitter in the brain. The chemical structure of dopamine consists of an amine
group attached to dihydroxyphenylalanine. Dopamine plays several important roles in the
human brain. Its major roles include the regulation of behavior, voluntary movement,
motivation and reward, mood changes, attention, and learning. Dopaminergic neurons
are the neurons that transmit dopamine. They are found predominantly in the Ventral
Tegmental Area (VTA) of the mid brain, the Substantia Nigra pars Compacta, and the
arcuate nucleus of the Hypothalamus.
Biosynthesis of Dopamine
Biosynthesis of dopamine starts with tyrosine. Tyrosine is an essential amino acid
that is found in surplus amounts in the diet. A low affinity amino acid transport system
transports tyrosine up to the brain and from the brain extracellular fluid into
dopaminergic neurons. Once inside the dopaminergic neurons, L-tyrosine is converted
into dihydroxyphenylalanine (L-DOPA), by hydroxylation of L-tyrosine. This is done by
the cytosolic enzyme, Tyrosine Hydroxylase (TH)(4). This conversion of Tyrosine to LDOPA is the rate limiting step in the biosynthesis of Dopamine. Another enzyme that is
indirectly responsible for the production of L-DOPA is dihyrodopteridine hydroxylase,
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which catalyzes the recycling of the essential cofactor tetrahydrobiopterine to
dihydrobiopterine.
The next step in the biosynthesis of dopamine is the cytosolic conversion of LDOPA to dopamine. This conversion is carried out by the enzyme Aromatic Amino Acid
Decarboxylase (AADC) (4). The rate of conversion of L-DOPA to dopamine is so swift
that there is almost no L-DOPA left in the brain under normal conditions.
Following the biosynthesis of dopamine, dopamine is transported from the
cytoplasm to specialized vesicles by an active transport mechanism, and these vesicles
store dopamine until it is released by exocytosis (4). These specialized vesicles are
derived from the endosomal compartment. An active transport mechanism is used to
transport dopamine into the vesicles, and is regulated by the Vesicular Monoamine
Transporter (VMAT).
The dopaminergic system is one of the major targets of addictive drugs. This is
because dopamine is the primary neurotransmitter involved in the reward circuitry of the
brain.
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Figure 1: Schematic model of a C.elegans DA neuron containing known and
predicted genes involved in DA biosynthesis and metabolism - TH, tyrosine
hydroxylase; AAAD, aromatic L-amino acid decarboxylase; VMAT, vesicular
monoamine transporter; DAT-1, dopamine transporter; DOP1, D1-like DA receptor;
DOP2, D2-like DA receptor.
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Association of Amphetamines to Dopamine
It has been a known fact that most addictive drugs function by increasing the
synaptic dopamine via various synaptic modulations, which are significantly distinct
from regular physiological circumstances (1). Amphetamine stands out from other
addictive drugs in the manner by which it regulates the increase of synaptic dopamine.
Amphetamine achieves the increase of extracellular dopamine by promoting efflux from
synaptic terminals (5). Acute administration of amphetamine induces phosphorylation of
cAMP response element-binding protein (CREB) and increases expression of a number
of immediate early genes (IEGs), such as c-fos (6). On the other hand, chronic exposure
to amphetamine induces delta FosB (∆FosB), which plays an essential role in long-term
adaptive changes in the brain (7). Amphetamine affects dopamine signaling in multiple
ways. It has been shown that amphetamine is a transporter substrate of DAT that is
dependent on temperature. It was shown that the accumulation of amphetamine was
prevented by the presence of DAT reuptake inhibitors like cocaine (8). Galli and
coworkers showed that amphetamine can stably efflux dopamine through DAT.
The first series of studies on the mode of action of amphetamines showed that
amphetamines could release dopamine in cells that expressed dopamine transporter
(DAT) (9) and that this release was greatly increased in cells that co-expressed VMAT,
suggesting a role for both DAT and VMAT in the release of dopamine. Studies using
knockout mice and cyclic voltammetry showed that knockout mice that did not express
DAT were unable to exhibit AMPH mediated dopamine release (10, 11). Moreover,
AMPH mediated dopamine release was reduced by 65% in VMAT knockout animals
(12).
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Effect of Amphetamine on Vesicular Monoamine Transporters
It has been widely accepted that vesicular monoamine Transporter (VMAT) is an
important mediator of amphetamine mediated dopamine release. There are two basic
mechanisms which have been suggested on how AMPH exerts its effects on the
monoamine transporters: The Weak Base Hypothesis and Redistribution of VMAT (2).
The Weak Base Hypothesis
Amphetamines are lipophilic weak bases with a pK of 9.9. It has been suggested
that the interior of the catecholaminergic vesicles is acidic, like that of the chromaffin
granules (pH 5.5). Therefore it is assumed that once amphetamine gains access inside the
vesicles, it starts accepting protons, which in turn alkalinizes the interior of the vesicles
(2). According to the weak base hypothesis, AMPH enters the cells through diffusion and

from there it gains access inside the vesicles. Once inside the vesicles, it disrupts the
proton electrochemical gradient that is required by the vesicles in order to sequester the
cytosolic dopamine. The disruption of the electrochemical gradient leads to inability of
the vesicle to sequester intracellular dopamine, which finally leads to increased
accumulation of intracellular dopamine. High concentration of cytosolic dopamine and a
disrupted concentration gradient leads to reverse transport of dopamine via the dopamine
transporter (DAT) (13). The mode of action of amphetamines according to the weak base
hypothesis depends solely on the weak base properties of AMPH and does not require the
direct action of amphetamines on dopamine transporters (2). This mechanism is widely
accepted although there are several questions that still need to be answered before this
model can be unanimously accepted.
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Redistribution of VMAT
Apart from being responsible for disrupting the proton gradient, amphetamines
also appear able to hamper the ability of VMAT to uptake dopamine. It has been found
that administration of a high dose of amphetamine and its derivatives (METH and
MDMA) can rapidly reduce the ability of VMAT to uptake dopamine. This occurs along
with a reduction in the ability of VMAT ligands like dihydrotetrabenazine (DHTBZ) to
bind to VMAT (14). It was also found by immunohistochemistry studies that immediately
after high dose administration of METH, a decrease in the immunoreactivity of VMAT
from the cytosolic fraction to a location that was not retained in the preparation of the
synaptosomes with a concurrent decrease in the vesicular dopamine (15, 16). This
suggests that there is a redistribution of dopaminergic vesicles in addition to a decrease in
the amount of dopamine in the vesicles, although clear mechanism is yet to be known.

Effect of Amphetamines on Dopamine Transporter
Vesicular neurotransmitters transporters like plasma membrane transporters use
electrochemical energy from ion gradients. In principle, membrane transporters should
possess at least one mechanism, known as a gating mechanism, which acts to alter their
conformation and prevents superfluous substrates from diffusing through the membrane.
A study conducted using low concentration of radiolabelled amphetamine,
showed that Dopamine transporter blockers such as methylphenidate, cocaine and
methamphetamine were able to block the accumulation of amphetamine. This suggested
that amphetamine is indeed a substrate of DAT (8).
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Further studies using transfection of DAT into cells have confirmed the fact that
amphetamine is a substrate of DAT (3). DAT blockers such as cocaine act by inhibiting
inward current as a result of Na+ co-transport, but amphetamine activates inward
currents, which identifies amphetamine as a substrate as it activates co-transport (17).
The most widely accepted model used to explain the uptake of amphetamine
release at plasma membrane transporters is the facilitated exchange diffusion model. The
concept was introduced by Stein in 1967 in order to explain glucose transport. According
to the facilitated exchange diffusion model, in order to aggregate cellular glucose, the
binding site acquires a molecule of glucose extracellularly and then translocates the
molecule across the plasma membrane in order to release the molecule in the cytosol. In
case of reverse transport, the binding site facing the cytosol binds another molecule of
cytosolic glucose and releases this molecule extracellularly after it re-traverses to the
external site.
In 1969, Bogdanski and Bogie extended this idea to catecholamine transporters.
Now the facilitated exchange diffusion is the most prominent model used to explain the
effect of catecholamine release by amphetamines at the plasma membrane uptake
transporters.
In order to explain action of amphetamine on membrane transporters, the
facilitated exchange diffusion model states that amphetamine induces the release of
dopamine by translocation of amphetamine as a substrate of DAT and suggesting that the
DAT binding site faces the cytosol. Dopamine, having a higher concentration in the
cytosol, binds to the DAT binding site and increasing the rate of reverse transport of
Dopamine. A molecule of dopamine released by the reverse transport is followed by the
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uptake of an amphetamine molecule. Thus, there would be one molecule of dopamine
released per molecule of amphetamine that is acquired. Although the facilitated exchange
diffusion model is widely used to explain the action of dopamine release, it is not yet
sufficient enough to explain all the mechanisms that are associated with amphetamine
and dopamine release (1).

Advantages of the Caenorhabditis elegans as a model organism
The present study was conducted on the invertebrate Caenorhabditis elegans, a
nematode commonly known as the round worm. The worm has several characteristics
that make it an ideal candidate for neurological studies. First, the worm can be easily
maintained in the laboratory. They are generally grown in agar plates that have been preseeded with bacteria. It has a large brood size which yields around three hundred worms
per hermaphrodite animal within a short span of three days. This rapid growth of the
worms and their large brood size allows for a wide variety of molecular, genetic and
cellular studies. Another advantage of using C.elegans is the fact that the animal is
transparent. This transparency helps in the studying various morphological features of the
organism. Reporter genes can be easily constructed in C.elegans and this helps in better
understanding the neurological morphology and also aids in the examination of protein
expression. It is also very easy to perform gene-knock out studies in C.elegans using
RNA-mediated interference (RNAi) technology (18).
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Caenorhabditis elegans Life Cycle
The life cycle of C. elegans is comprised of three basic stages which include the
embryonic stage, larval stage, and adult worm and takes 3 days to complete (figure 2).
The larval stage has four sub-stages (L1-L4) which include the synthesis of a stage
specific cuticle layer with the subsequent shedding of the old stage (19). The embryonic
stage lasts for 9 hours. Immediately after the hatching of the egg, the L1 larval stage sets
in. In the L1 larval stage, the nervous system, reproductive system, and the coelomocyte
system starts to develop. The L1 larval stage lasts for about 12 hours, after which the
larva enters the second L2 larval stage which may last upto 8 hours. There are a few cell
divisions during the L2 stage, during which the nervous system and the reproductive
system are further developed. At the end of L2 stage, the animal may enter an arrested
state called the dauer larva stage. This happens when the environmental conditions are
not favorable for further growth. The environmental factors include population density,
absence of food or starvation, and high temperature. If any of the environmental factors
are present, a pheromone is secreted that act as a signal to trigger the formation of a
morphologically distinct L2 stage larva designated L2d. The critical period for this dauer
signal begins after the middle of the first larval stage. The L2d larva retains the potential
to form either a dauer larva or an L3 larva depending on the environmental parameters. If
the environment continues to be disadvantageous, L2d molts into a dauer. The dauer state
is a non-aging state, as its duration does not affect postdauer life span. During the dauer
state, feeding is arrested indefinitely and locomotion is reduced. The dauer state ends
with the onset of favorable environmental conditions.

11

In the L4 larval stage, which starts 7 hours after the hatching of the egg, the
gonadogenesis is completed. Approximately at 45-50 hrs post hatch at 22-25°C, a newly
matured hermaphrodite lays its first cells, hence completing its 3-day reproductive life
cycle. The adult hermaphrodite produces oocytes for about 4 days and after this fertile
period of 3-4 days, the mature adult lives for an additional 10-15 days.
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Figure 2: Life cycle of C. elegans. 0 min is fertilization. Numbers in blue along the
arrows indicate the length of time the animal spends at a certain stage. First cleavage
occurs at about 40 min. post-fertilization. Eggs are laid outside at about 150 minutes postfertilization and during the gastrula stage. The length of the animal at each stage is
marked next to the stage name in micrometers.
Reprinted with permission from David H Halle at www.wormatlas.org
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Caenorhabditis elegans Neurobiology
One of the major advantages is the fact that C.elegans has only 302 neurons. All
of the 302 neurons of the worm have been mapped and characterized. Moreover, the
major interactions between the neurons are also known. The neurobiology of C.elegans is
very similar to that of mammals and the worm shares a significant amount of
conservation of neuronal pathways with its mammalian counterpart. The C.elegans
nervous system constitutes of ion channels, neurotransmitters, receptors synaptic
components and vesicular transporters which are very similar with mammals (18, 20).
C.elegans has eight dopaminergic neurons. Four of the dopaminergic neurons are
symmetrically arranged in the cephalic cells (CEPS), two dopaminergic neurons are
present bilaterally in the anterior derids (ADE) in the head, and two neurons are present
bilaterally in the posterior derids (PDE) (Figure 3).
Role of Dopamine Signaling in C.elegans
Dopamine plays several important roles in C.elegans. Dopamine is essential for
locomotion, egg-laying, defecation, basal motor activity, sensation/response to food
sources, habituation to touch, and several other mechanisms in worms. Exposure of
animals to dopamine has been found to affect locomotion, feeding, and egg-laying
behavior in worms by decreasing it. This hypothesis has been confirmed by data showing
that when the uptake of dopamine is blocked by the use of dopamine receptor antagonists
like haloperidol and chlorpromazine, it reversed the effect by resuming normal
locomotion and egg-laying (21). Moreover, mutation studies on genes that affect
dopamine storage and uptake have shown that the locomotion of the animals is not
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affected by the presence or absence of a food source, whereas under normal physiological
conditions, the worms move at a slower pace when food source is present. In the absence
of an adequate food source, the worms tend to move faster (22). Dopamine signaling also
seems to play a role in the mating behavior of worms. It has been found that laser
ablation of the male tail dopaminergic neurons makes the males unable to locate the
vulva and results in failure in copulation. Similarly cat-1, cat-4, bas-1 and cat-2 mutant
male worms have been found to have less interest in mating while encountering a
hermaphrodite compared to wild type worm (18).
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Figure 3: Schematic of C. elegans Dopaminergic neurons. A- head showing
dopaminergic (DA) neurons on one side; each neuron has a bilaterally symmetric partner.
CEPD: dorsal cephalic neuron; CEPV: ventral cephalic neuron; ADE: anterior
deirid neuron. B- Schematic of C. elegans body showing locations of DA neurons,
including the PDE: posterior deirid neuron.
Reprinted by permission form BMC Neurosci., 2010, 11, 22, England: “A comparison of
experience-dependent locomotory behaviors and biogenic amine neurons in nematode relatives
of Caenorhabditis elegans.” Rivard,L.; Srinivasan,J.; Stone,A.; Ochoa,S.; Sternberg,P.W.;

Loer,C.M. copyright 2010 by BioMed Central.
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Effect of Amphetamine on the Dopaminergic Signaling Pathway
The general mode of action of amphetamine is increasing the amount of dopamine
in the synaptic cleft which finally heightens the response of the post synaptic neurons.
The mode of action of amphetamine in dopamine released has been studied by various
independent research groups. Initial studies using cocaine as the Dopamine transporter
(DAT) blocker and other AMPH antagonists suggested that although cocaine works by
binding directly to DAT (11), the mode of action of AMPH is more complex. A
significant effect of amphetamine administration is that it causes reverse transport of
dopamine via the DAT (23). As we know from previous sections, the main function of the
dopamine transporter is to pump dopamine that is not up taken by the dopaminergic
receptors back to the cytosol for vesicular storage and future release. Amphetamine
reverses the function of DAT where DAT is unable to transport any dopamine back to the
synapses. This effect of AMPH on DAT was shown in mice lacking DAT, where
amphetamines where not able to increase the levels of dopamine in the synapses (11).
Sulzer et.al have also shown that amphetamines can release monoamines by the
redistribution of the dopamine transporter from a vesicular to cytoplasmic pool, which in
turn promotes the reverse transport of dopamine from cytosol to the synapses(13). When
amphetamine is administered it does not have any charge; as it gradually traverses the
vesicle membrane, amphetamine gains a charge because of the lower pH of the synaptic
vesicles. As the concentration of amphetamine increases, the vesicular pH gradient
decreases. As the pH decreases, the energy required by the dopamine transporter to
uptake extracellular dopamine also decreases. Finally, amphetamine competes with the
17

dopamine for protons. This results in the diffusion of uncharged dopamine from the
vesicle. This reduced vesicular monoamine concentration and increased substrate
concentration creates a concentration gradient across the plasma membrane which leads
to the release of dopamine through reverse transport (9).
Amphetamine induces a manifestation in C.elegans known as SWIP (Swimming
Induced Paralysis). This manifestation is the outcome of increased dopamine in the
extracellular space which is not being cleared by the DAT. McDonald et al. was one of
the first groups to show the phenomenon. They showed when well-fed wild type and dat1 mutant worms were placed in liquid environment like water or M9 buffer, the wild-type
worms showed sustained thrashing even after 30 minutes in water. In contrast, when dat1mutant worms were placed in the same liquid environment, they demonstrated
symptoms consistent with paralysis within 6 minutes (24).
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Epigenetics
Epigenetics is a word that was coined by C.H. Waddington in 1942. The word
Epigenetics is derived from the Greek word ‘epi’, and roughly translates as above the
genome. In practice, the term epigenetics is used to refer to functional modifications of
the genome that do not involve a change in the overall nucleotide sequence of the
organism. Examples of functional epigenetic modifications include methylation,
acetylation, phosphorylation, ubiquitylation and others.
Epigenetic modifications can be broadly divided into two basic categories. One
group of modifications target DNA directly. Here, DNA can be directly modified at the
cytosine residues by either methylation or hydroxymethylation. In terms of regulation of
gene expression, cytosine residues may be predominantly situated in a cytosine-guanine
(CG) dinucleotide rich area, referred to as CpG islands in vertebrates. CpG islands are
regions in the genome where there is a high frequency of CpG sites, and these islands are
often localized around gene promoters. The “p” here refers to the phosphodiester bond
between cytosine and guanine indicating that the Cytosine and the guanine residue are in
the same strand, next to each other connected by a phosphodiester bond. The mechanism
by which a DNA methylation affects transcription is a two-step process. First, the
methylation of the DNA at the CpG site by specific proteins known as DNA
methytransferases (DNMT) (25). Second, DNA methylation may directly interfere with
the sequence-specific binding of some of the transcription factors, thereby reducing
transcriptional activation. Another method by which the DNA methylation can directly
affect transcriptional regulation is by the specific recognition of methylated DNA by the
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methyl-CpG-binding domain (MBD) proteins that can cause transcriptional repression.
(26).

A second mode of epigenetic modifications involves chromosomal proteins such
as histones. These modifications are covalently carried on the histone tails and the
modifications can be stable enough that they may be passed on to multiple generations
(27, 28). Histones are a class of highly conserved alkaline proteins that package the DNA

in an ordered manner into structural units known as nucleosomes. The core of the
nucleosome is made up of four histones namely, H2A, H2B, H3 and H4. This octameric
histone protein complex is made up of two H2A and H2B heterodimers and two H3 and
H4 tetramers. Each of the histone proteins consist of a structural domain and an aminoterminal tail domain. This amino-terminal tail domain is the site of major epigenetic
histone modifications (29). Histone modifications have a major impact on the functioning
of the organism. Known regulatory roles associated with histone modifications include
the regulation of cell division, cell differentiation, transcription, gene activation, and gene
repression. Histone modifications are essential during cellular differentiation where they
help direct a cell to know which genes are to be turned on and turned off (27). Histone
modifying enzymes are required to alter the histone modifications like methylation,
acetylation etc. Some of the histone modifying enzymes are Histone methyltransferases
(HMTs), Histone acetyltransferase (HATs), Histone demethylases and Histone
deactylases (HDACs) to name a few. These enzymes add or remove acetyl groups or
methyl groups at the tail of the specific histone proteins and the resulting histone code
plays a role in the regulation of gene expression. The addition of a methyl group or an
acetyl group can lead to the gene activation or gene repression depending on the specific
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H3K4me3

H3K36me3

H3K27me3
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Figure 4: Average enrichment profiles of histone modifications A) Average
enrichment profiles of histone modifications associated with active genes around the
transcription start site. B) Histone Modifying Enzymes (Histone Methyltransferase and
histone demethylase) of H3K4me3, H3K27me3 and H3K36me3 in C.elegans.
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histone residue being modified. There are certain histone marks that are associated with
gene activation while there are other histone marks that are associated with gene
repression. Active marks are predominantly associated with the euchromatin where the
chromosomal structure is such that it allows the transcription factors and other associated
proteins to access the genes and allows for the transcription of the genes. Repressive
marks are predominantly associated with heterochromatin, regions of chromatin where
the chromatin is compacted and reduces the ability of the transcriptional machinery to
bind to the chromatin and reducing gene transcription. Examples of several of the
activation marks are H3K4me3 (trimethylation on lysine 4 of histone H3)(30), and
H3K36me3 (trimethylation on lysine 36 of Histone H3).

Repressive histone

modifications include H3K9me2/3 (di/trimethylation on lysine 9 on Histone H3) and
H3K27me3 (trimethylation on lysine 27 of Histone H3), among others.

In higher

organisms, heterochromatin is a region that is enriched in the repressive histone marks
which include H3K27me3, H3K9me2/3. Euchromatin is enriched with active histone
marks such as H3K4me3. The pattern of enrichment of histone marks (active or
repressive) with the specific chromatin is highly conserved in eukaryotes from flies to
mammals (31). The chromatin modifying enzymes that bring about the histone
modifications have been found to play an important role in the development of an
organism at all stages of the development of the organism.
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Importance of Epigenetics
Stable histone modifications play an important role in deciding various factors in
the development and the functioning of an organism. Histone modifications have been
known to impart roles in vulval cell fate specification, lifespan determination, genomic
stability, embryonic and germline development in various organisms. H3K27me3, a
repressive histone mark that is associated with facultative heterochromatin, is known for
increasing the lifespan in C.elegans (32). It has been found that UTX-1 increases the
lifespan in C.elegans in a manner that is dependent on insulin signaling pathway (32). The
knockdown of UTX-1, an H3K27me3 demethylase enzyme, increases the levels of
H3K27me3. This high level of H3K27me3 maintains the chromosomal repression and
this transcriptional repression is thought to play a role in increasing the lifespan. This is
also backed by the finding that as an organism ages, the enrichment levels of H3K27me3
falls. Another important role of the H3K27me3 histone modification is that it is essential
for the transmission of specific chromatin and gene expression patterns from the mother
to the daughter cells (33, 34).
H3K36me3 is an active histone mark that has several important functions. The
H3K36me3 modification is enriched on histones associated with the gene bodies of
actively transcribing genes. This suggests that the H3K36me3 modification is associated
with the transcription process. While H3K9me3 a repressive histone mark is often
enriched at the promoter regions of silent genes. Another important role of the
H3K36me3 modification is thought to be its role in splicing (35). Splicing is modification
of pre-mRNA where non-coding sequences of the nucleotides within a gene (introns) are
removed and the coding sequences (exons) are joined in order to form the mature mRNA
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that can be utilized by the translational machinery to make proteins. In 2009, KolasinskaZwierz et.al conducted a genome-wide map of histone H3 tail methylations in order to
gain deeper insight in to the chromatin function in C.elegans. They found that the
H3K36me3 histone modification is present preferentially on the exons, but reduced on
histones associated with intronic regions (36). They also found that the H3K36me3 exon
marking is dependent on transcription and it is found at a lower level on exons that are
alternatively spliced (36). This suggests that the H3K36me3 has a patterning mechanism
that is dependent on splicing. They also found that this splicing dependent patterning
mechanism of the H3K36me3 modification is present not only in C.elegans but is
conserved evolutionarily in mice and humans.
The H3K4me3 histone modification is considered to be an activating histone
mark. It is associated with the activation of transcription (30). The H3K4me3 histone
mark plays an important role in the development of an organism. It has been found that
the H3K4me3 mark is sometimes associated with the repressive histone mark H3K27me3
at select gene loci. These loci are generally associated with the developmentally regulated
transcription factors that need to be activated at certain appropriate times only (37, 38).
H3K4me3 plays another important role in the development of an organism apart from
gene activation. It has been found in C.elegans that the H3K4me3 mark is also
responsible for controlling the lifespan of the organism and that this epigenetic
information is carried to multiple generations in C.elegans (39). Recent study has shown
that a deficiency in H3K4me3 chromatin modifiers can increase the lifespan of the
progeny through three subsequent generations (39).
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There is a high degree of conservation between the chromatin modifications and
the enzymes that regulate these modifications (methylase, demethylase and others) across
species. Keeping the high degree of conservation in mind, genetic approaches used in
C.elegans are expected to shed light in the functional importance of epigenetic gene
regulation in normal development and trans-generational inheritance in other species,
including humans. In this study, C.elegans is used as a model organism to study the effect
of drugs on these chromatin modifiers.
Epigenetics and Addiction
It has been hypothesized that environmental stimuli may induce epigenetic
changes which can then be inherited by future generations. Addiction is a known human
disease with clear trans-generational impact and susceptibility, but lack of a defining
genetic change that can explain this phenomenon. To date, only limited data exists
suggesting a link between addictive drug use and epigenetic changes in the brain.
Specifically, drugs of abuse are known to induce changes in histone acetylation patterns
in the brain and cocaine has been found to globally increase the acetylation levels of
Histone H3 and H4 in Nucleus accumbens in the brain (40, 41).
Transcription Factors Associated With Addiction
There are several key transcription factors that are associated with addiction, and
modulation of transcription factors are one of the classical mechanisms of gene
expression regulation. Psychostimulant drugs and opiates are known to regulate gene
expression through their action on key transcription factors. These regulatory actions can
lead to further consequences like increased self-administration of drugs, changes in the
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rewarding effects of the drug, etc. Some of the key transcription factors that are known to
be associated with drug addiction are as follows:
∆FosB- It is encoded by the fos B gene and shares homology with other Fos family of
proteins. Fos family transcription factors are essential for the cell proliferation,
differentiation etc. ∆fos B heterodimerizes with Jun family of proteins to form the
Activator protein (AP-1). AP-1, later on binds to AP-1 sites in genes in order to regulate
transcription.
It has been found that psychostimulant drugs like cocaine affect ∆fosB that leads
to a long lasting expression. ∆FosB has been found to be induced in the Nucleus
Accumbens and in the dorsal striatum (42). ∆FosB is a C-terminal truncation of FosB
which is generated by the alternative splicing. This alternative spliced product lacks the
degron domains. This alternative splicing and phosphorylation at several sites increases
the stability of the protein (43). It has been found that overexpression of ∆FosB in the
Nucleus Accumbens and dorsal striatum causes increased locomotor sensitivity to
cocaine and this may lead to increased cocaine self-administration (44). Studies using
virus-mediated overexpression have shown that induction of ∆FosB by cocaine aids in
the ability of cocaine to induce the cognition-disrupting effects of acute drug exposure.
Moreover, overexpression of ∆JunD, which is an antagonist of ∆FosB in the Nucleus
Accumbens blocks the effects of ∆FosB mediated effects of cocaine (43).
CREB (cyclic AMP response element binding protein) - CREB is a transcription factor
that has multiple functions in the brain. It is responsible for the formation of long-term
memory in the brain (45). In mice, it has been found that deletion of CREB in the embryo
leads to death immediately after birth. CREB acts as a transcription factor only after it
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has been phosphorylated at Serine 133 and binds to a cAMP response Element (CRE). It
has been found that cocaine and amphetamine increases CREB activity both acutely and
chronically in both the Nucleus Accumbens and in the dorsal striatum in the brain (46).It
has also been found through various studies that overexpression of CREB decreases the
rewarding effects of cocaine and that of opiates in the D1-D2 Medium Spiny Neurons
(MSN) in the Nucleus Accumbens, an effect that increases the self-administration of drug
through negative reinforcement (47).
There are other transcription factors like NFκB (nuclear factor κB), MEF-2
(myocyte enhancing factor-2) and others that have been found to be regulated by drugs of
abuse and also by nicotine and alcohol.
Histone Tail Modifications associated with Addiction
Unraveling the histone code is an ongoing challenge in the epigenetic field. The
challenge is based on the need to understand both the significant number of possibilities
of complex histone modification patterns that may exist in a genome, and reconcile this
data with the possibility that a particular pattern may have diverse meaning depending on
the individual gene in question. In the recent years, there has been a dramatic acceleration
of progress in the development of various new tools and techniques for mapping of the
epigenetic state of any particular gene and the genome as a whole. This emergence of
new technology has dramatically increased our understanding of the functional role of the
histone code, and aided in deciphering the functionality of epigenetic signatures as they
pertain to gene expression.
Drugs of abuse have also been found to be associated with changes in the
epigenome. Evidence has started to accumulate regarding the effect of various drugs of
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abuse in inducing histone acetylation in the brain. At the global level, studies have shown
that acute or chronic exposure to cocaine increases the acetylation of H3 and H4 in the
Nucleus Accumbens (40, 41). Although there is an increase in the acetylation of H3 and
H4 at the global level, interestingly though, there is decrease in the acetylation after
chronic cocaine at the local level for many genes. Simultaneously, another case study
associated with alcohol withdrawal has shown that there is an increase in the levels if
Histone Deacetylase (HDAC) activity which is associated with reduction in histone
acetylation in mouse (48). The above examples emphasize the fact that there is a need for
further research in order to define the effect of drug of abuse on histone acetylation in the
brain and also to pinpoint the specific histone modifying enzymes that mediate this
regulation.
Recent findings have pointed towards the fact that the change in the acetylation of
H3 and H4 with cocaine usage has been linked to sirtuin proteins which are a class of
Histone deacetylases. Genome wide studies at the chromatin level in the Nucleus
Accumbens after chronic cocaine administration revealed the upregulation of two sirtuin
proteins SIRT1 and SIRT2. The induction of sirtuin protein is associated with increased
H3 acetylation and also with an increase in the binding of ∆FosB at its gene promoters
(49).

Histone methylation has also been linked to regulation by drugs of abuse. Chronic
cocaine has been known to reduce the global levels of Histone 3 lysine 9 dimethylation
(H3K9me2) in the nucleus accumbens, which is thought to be mediated by the down
regulation of the two histone methyltransferase G9a, and the G9alike proteins (GLP) (50).
Although there is a decrease in the global levels of H3K9me2 in the NAc, interestingly,
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genomewide screening revealed significant decreases in the enrichment of H3K9me2 at
the promoters of various genes, further suggesting that the epigenetic mark at a specific
gene is a not a true representation of the changes at the global level (49).
Chronic cocaine is also known to downregulate the repressive histone mark
H3K9me3 (histone 3 lysine 9 trimethylation) in the NAc. The H3K9me3 is a mark that is
predominantly associated with heterochromatin. This decrease in the H3K9me3 levels is
associated with a decrease in the total amount of heterochromatin in the NAc (51). The
above observations draws light towards the profound effects that drugs of abuse can exert
on the epigenome, although the functional implications of this regulation is not clearly
understood.
It is now widely accepted that epigenetic modifications lead to heritable, but
reversible, changes in gene expression without causing alterations in DNA sequences.
Studies have shown that a deficiency in trimethylated H3K4me3 chromatin modifiers can
increase the lifespan of the progeny until three subsequent generations (39). As previously
discussed; environmental influence has been known to induce changes in epigenetic
modifications. This suggests that drugs of abuse might also induce changes in epigenetic
modifications. Studies by Renthal et al. in 2009 (51) have shown that repeated
administration of cocaine alters gene regulation by inducing changes in histone
modifications. They showed that chronic use of cocaine alters transcription by changing
the acetylation states of histones H3/H4 and also the methylation states of H3K9 and
H3K27. This observation advocates that drug of abuse can alter gene expression by
inducing changes in epigenetic modifications.
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Amphetamine treatment has been shown to induce a phenotype known as SWIP
(Swimming Induced Paralysis) in C.elegans (24). Recent SWIP study indicates that
animals exposed to amphetamine during embryogenesis/developmental stage show
Swimming Induced Paralysis in F0 and this phenotype is also observed in F1-F3
generations. Moreover, Carvelli et al (5) has indicated that DAT plays an important role
in the ability of amphetamine to increase extracellular dopamine. They showed that
amphetamine treatment produces SWIP in “a time- and dose-dependent manner” in wildtype worms but this ability to produce SWIP is greatly hampered in DAT-1 knockout
animals. This observation leads us to hypothesize that amphetamine treatment might
induce changes in histone modifications, specifically histone methylation at the promoter
of the genes involved in dopamine synthesis and uptake, as drugs of abuse have been
known to induce histone modifications as shown by Renthal et al. We propose that an
epigenetic mechanism may be responsible for the altered response to amphetamine
observed by Carvelli et.al. in subsequent generations of worms (unpublished data).
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Chapter 2
Materials and Methods
Cell Culture
HT1080 (fibrosarcoma) cells were obtained from American Type Culture
Collection (ATCC, Rockville, MD) and used as a control in several studies. The HT1080
cells were grown on 75cm2 canted neck cell culture flasks. The cells were grown in
Eagle’s Minimum Essential Medium (EMEM) supplemented with 10% Fetal Bovine
Serum (FBS). The cell cultures were maintained at 37⁰C in a 5%CO2: 95% air
atmosphere and fed with fresh growth medium every three days. Upon reaching
confluency, the cell culture medium was discarded; the cells were rinsed briefly with
Phosphate Buffered Saline (PBS). 3.0ml of Trypsin-EDTA solution (0.25%w/v) was
added and the flasks were observed under microscope until the cell layer was dispersed.
Following dispersion, the cells were subcultured with fresh media (EMEM) at 1:4 ratios
or harvested for RNA, DNA, or protein extraction.
Protein Extraction
Cytoplasmic and nuclear protein extracts from HT1080 cells were prepared using
NE-PER Nuclear and Cytoplasmic Reagents (Pierce Biotechnology, Rockford IL). The
NE-PER Nuclear and Cytoplasmic Reagents kit allows stepwise separation of
cytoplasmic and nuclear extracts from mammalian cells or tissues. HT1080 cell lysates
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were prepared by adding Trypsin-EDTA solution (0.25%w/v) for the detachment of the
cells from the surface of the culture flasks. The cells were then collected by pipetting and
then centrifµgation at 1000 times g for five minutes. The cell pellets were stored at -80⁰C
for further use. 20 µl of cell lysate was used to make the protein extracts. The cell pellet
was washed with Phosphate Buffered Saline (PBS) by centrifµgation at 500 x g for five
minutes. After Phosphate Buffered Saline was removed by pipetting, 200 µl of
Cytoplasmic Extraction Reagent I (CER I) was added and the cells were vortexed for15
seconds. After incubating the cell pellet on ice for 10 minutes, 22 µl of Cytoplasmic
Extraction Reagent II (CER II) was added and the tube was vortexed for 5 seconds and
incubated on ice for 1 minute. The cells were vortexed again for 5 seconds and
centrifµged at highest speed (> 16000xg). Immediately after the centrifµgation, the
supernatant was carefully transferred to fresh pre-chilled 1.5ml centrifµge tube and stored
at -80⁰C for further use. 100 µl of Nuclear Extraction Reagent (NER) was added to the
cell pellet and vortexed for 15 seconds after 10 minutes incubation on ice for a total of 40
minutes. The tubes were then centrifµged at highest speed (> 16000xg) for 10 minutes.
Immediately after the centrifµgation, the supernatant was carefully transferred into prechilled 1.5ml centrifµge tubes and stored at -80⁰C for further use.
Immunoblot
Western blots were performed using pre-cast (4-20%) Tris – glycine gels from
Bio-Rad, Inc. The gels lanes were loaded with 15µg of nuclear and cytoplasmic protein
fractions. Laemlli buffer (Bio-Rad, Inc.) was used for sample prep prior to
electrophoresis. Electrophoresis was conducted using running buffer (1gm SDS, 100ml
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10X Tris Glycine Buffer, 900ml Distilled water) for 1 hour at 100 constant volts. The
gels were immersed in running buffer for 20 minutes.
After 20 minutes, the gels were subjected to transfer on Polyvinylidene fluoride
membrane (PVDF membrane). The preferred method of transfer was the semi-dry
transfer method. Transfer was conducted for 1 hour at 100 constant milliamps. Since
PVDF membrane has high affinity for proteins and it can bind to both target and nonspecific proteins, in order to prevent the binding of non-specific proteins, the remaining
binding surface of the membrane must be blocked in order to prevent the non-specific
binding of the antibodies. Therefore, after the transfer, the PVDF membranes were
incubated overnight in blocking buffer at 4⁰C with agitation. Two different blocking
buffers were used. For the detection of anti-histone H3 antibody (Abcam 1791), milk (5%
milk, 0.05% Tween 20 1X Tris Buffered Saline) was used as the blocking buffer and for
the detection of antibodies against histone modifications {(Anti-histone H3K27me3
(Millipore 07-449); Anti-histone H3K4me3 (Millipore 07-443) and Anti-histone
H3K36me3 (Abcam 9050)}, BSA was used as the preferred blocking buffer (5% BSA,
0.05% Tween 20 1X Tris Buffered Saline). In order to visualize the protein of interest,
the membranes were incubated with the primary antibody (Anti-Histone H3 1:1000;
Anti-histone

H3K4me3

1:5000;

Anti-histone

H3K27me3

1:2500;

anti-Histone

H3K36me3 1:1000) for 1 hour in a solution of either BSA blocking buffer or milk
blocking buffer with agitation. Membranes were then rinsed and washed thrice in wash
buffer (0.1% tween 20, 1X Tris buffered Saline) for 20 minutes each. Affinity purified
goat anti-rabbit IgG Horse Radish Peroxidase-linked secondary antibody was diluted to
1:1000 in either Milk or BSA blocking buffer and applied to the membranes for 1hour at
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room temperature with agitation. The membranes were then rinsed and washed thrice in
wash buffer (0.1% tween 20, 1X Tris buffered Saline) for 20 minutes each. The protein
bands were developed using Immun-Star WesternC Chemiluminescent Kit (Biorad).
Synchronization of worm cultures
Isolated eggs were resuspended in 100-200 ul of sterile water and seeded onto
NGM agar plates without bacteria. The eggs were hatched by incubating the plates at 2024⁰C for 12-16 hours. After hatching, the larvae were rinsed off the plates into a 15 ml
conical tube with sterile water or M9 buffer. The worms were pelleted by brief
centrifugations and then resuspended in a small volume of sterile water. Finally, 15mm
Petri plates were seeded with washed larvae. The larvae were then allowed to grow until
reaching the young adult stage.
Worm Egg isolation
Adult synchronized worms were washed off agar plates with Milli-Q water into a
15 milliliter sterile conical tube such that 7 petri plates of worms were washed into one15
ml conical tube. The contents of the tubes were mixed thoroughly and the tubes were then
centrifuged at 1200 rpm (~450 g) for one minute in a swinging bucket rotor. The pellet
was washed 5 times with Milli-Q water until the supernatant becomes clear. After the last
wash the worms were lysed with bleach and NaOH (Fresh Clorox 2.0mL, 10N NaOH
0.5mL and sterile water 7.5mL). The worms were rocked gently during lysis. Finally, the
lysis was monitored by viewing the worm suspension under the microscope. The lysis
reaction was stopped when ~50% of the worms were lysed (approximately 6 minutes of
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lysis). The lysis reaction was stopped by mixing the worm suspension with egg buffer
and immediately spinning the worm suspension at 1200 rpm for 3 minutes.
The supernatant was decanted using a sterile plastic pipette and the pellet was
washed three times by re-suspending the pellet with egg buffer and spinning the tubes at
1200 rpm for three minutes. After the last centrifugation, the excess buffer was carefully
removed using a sterile transfer pipette. The eggs were removed from the cell debris by
centrifugation in a 60% sucrose solution. For this, the lysed cell debris along with eggs
was re-suspended in 5mL of sterile water and 5mL of 60% sterile sucrose solution. The
mixture was vortexed and then centrifuged at 1200 rpm for 6 minutes using a swinging
bucket rotor. After the centrifugation, the eggs were collected from the top layer (near the
meniscus) using a sterile transfer pipette and transferred to a new 15mL conical tube.
The collected eggs were washed thrice using sterile water. Then the eggs were resuspended in 6mL M9 buffer and washed vortexing the tubes and then spinning the tubes
at 1200 rpm form two minutes. After the centrifugation, the tubes supernatant was
discarded and the eggs were transferred into a single tube.
Treatment with amphetamine
One half of the eggs were treated with Amphetamine (100mM Amphetamine
stock was used to a final concentration of 1mM) for 15 hours till the worms reached L4
stage. After treatment, all of the worms were collected by washing with M9 buffer from
the petri plates in order to make sure that no e.coli was collected.
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Worm Protein Preparation
A small amount of worms were taken in an centrifuge tube and briefly centrifuged
in a mini centrifuge in order to remove excess media. The pellet size was roughly
measured and to it an equal volume of 1X PBS was added. Then an equal volume of 2X
Laemmli buffer containing DTT was added. The mixture was boiled for 5 minutes and
then immediately cooled at -80⁰C. Later on the mixture was sonicated in a Branson
sonicator for 15 minutes at the highest setting for 30 minutes on and 30 minutes off cycle.
Chromatin Immunoprecipitation (ChIP)
Crosslinking
100ul of worms were flash-frozen in liquid nitrogen and ground to a fine powder in liquid
nitrogen using a mortar and pestle to a fine powder. The worm powder was incubated in
PBS containing 1% formaldehyde for 10-15 minutes at room temperature. The reaction
was quenched by addition of 2.5M glycine to a final concentration of 125mM for 10-15
minutes with shaking at room temperature. The mixture was centrifuged at 1000 rpm for
5 minutes. Then the pellet was washed three times with 1X PBS having protease inhibitor
cocktail. After the pellet was centrifuged, the pellet was frozen in liquid Nitrogen and
stored at -80°C.
Sonication
The worm pellet was re-suspended in 900ul SDS lysis buffer with Protease Inhibitor
Cocktail. Then the pellet was sonicated in a Bioruptor water bath (Diagenode) at
maximum power for 30secs on and 30secs off for a total of eight pulses on. After the
sonication, the homogenate was centrifuged at 14,000 rpm for 15-20 minutes at 4°C in
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order to remove cellular debris. The sample purity was quantified by measuring the
260/280 ratio on a Biotek Epoch spectrophotometer. 3uL of the sheared chromatin
sample was run on 1% agarose gel in order to determine the resulting DNA fragment
size. The supernatant containing the sheared chromatin (chromatin extract) was frozen in
liquid nitrogen, and kept at −80 °C for immunoprecipitation.
Immunoprecipitation
The chromatin extract was thawed and ~100µg was distributed into individual tubes. The
chromatin was diluted with 500μl of chip dilution buffer. The chromatin was pre-cleared
for 1 hour at 4°C with 120μl of 1:1 slurry of Protein A agarose beads. 50μl of the precleared chromatin extract was stored separately as Input sample at -20°C.After the preclearing, the tubes were centrifuged at 2000 rpm for 2-3 minutes. 400μl of cleared
chromatin extract was taken in in 15 mL conical tubes and to each tube 3.6mL of ChIP
dilution buffer containing Protease Inhibitor cocktail was added.
To each tube the specific antibodies were added. The antibodies used were Anti-histone
H3K27me3 (Millipore 07-449); Anti-histone H3K4me3 (Millipore 07-443), Anti-histone
H3K36me3 (Abcam 9050) and Anti- Histone H3 (Abcam 1791). The cleared chromatin
containing antibody was incubated overnight at 4°C in a rotator.
Preparation of magnetic beads
50μl of Protein G and 150μl of Protein A magnetic beads were taken in a 1.5ml
centrifuge tube. To it, 1ml of blocking solution (0.5%BSA in1X PBS) was added and
mixed properly. The tube was placed in a magnetic stand and the after the beads settled to
the side of the tubes, the blocking solution was discarded. This step was repeated twice
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before finally re-suspending the magnetic beads in 1ml of blocking buffer. The 1.5ml
tube containing the magnetic beads was incubated overnight at 4°C with rotation.
Immunoprecipitation
The next day, 100μl of magnetic beads was added to each 15ml conical tube containing
the chromatin extract and the antibody and the conical tube was incubated for 3 hours in a
rotator at 4°C.
After 3 hours of incubation with the magnetic beads, 1ml of the mixture was transferred
to a pre-chilled 1.5ml centrifuge tube and the tube was left to sit on the magnetic rack for
a minute so that all the magnetic beads could bind to the walls of the tube. Once, all the
magnetic beads were able to bind to the side of the tube, the supernatant was discarded.
This step was repeated until all of the beads were collected.
Washes
The magnetic beads were washed for 10 minutes at 4°C with wash buffers. After 10
minutes the tubes were placed in the magnetic rack. The wash buffers used were
commercially available Low Salt Immune Complex Wash Buffer, High Salt Immune
Complex Wash buffer, Tris-EDTA Buffer (Millipore, Inc.)
Elution and Reverse Cross linking
After the last wash, the tubes were centrifuged at 960g for 3 minutes at 4°C in order to
remove any residual TE buffer. 210μl of Elution buffer was added and the mixture was
eluted for 15 minutes at 65°C. The tubes were then centrifuged at 16000 g for a minute at
room temperature. 200μl of the supernatant containing the chromatin was transferred to a
new 1.5ml centrifuge tube. The tubes were subjected to reverse crosslinking in elution
buffer for overnight at 65°C.
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The next day, 200μl of TE buffer was added to each tube and 8μl of 10mg/ml of RNase A
was added before the tubes were incubated at 37°C for 2 hours. 8μl of 10mg/ml of
Proteinase K was added to the tubes and the tubes were incubated at 55°C for 2 hours.
DNA extraction using Qiagen PCR Purification columns
5 volumes of buffer PB was added to the tubes and mixed properly. The mixture was then
applied to the column and the tubes were centrifuged at 13000 rpm for 1 minute. The
columns were washed with 750μl of PE buffer. The tubes were again centrifuged for 1
minute at 13000 rpm. Then 50μl of elution buffer EB was added to the tubes and the
tubes were centrifuged at 13000 rpm for 1 minute. The elution step was repeated again.
RNA Isolation
Homogenization
The samples were mixed with 1ml of TRIZOL reagent and the samples were frozen in
liquid Nitrogen. The tubes were vortexed for 30 seconds and again replaced in liquid
Nitrogen. After the tubes had frozen, the tubes were thawed at 37°C. This step of freezing
and re-thawing was repeated for 3-6 times. The tubes were checked under the microscope
to see if most of the worms were disrupted. Most worms (not 100%) should appear
disrupted under a dissecting microscope.
Phase Separation
The samples were incubated for 5 minutes at 15 to 30°C to permit the complete
dissociation of nucleoprotein complexes. Then 0.2 ml of chloroform per 1 mL of
TRIZOL Reagent was added. The samples were shaken vigorously by hand for 15
seconds and incubated at 15 to 30°C for 2 to 3 minutes. The samples were then
centrifuged at 12,000 x g for 15 minutes at 2 to 8°C.
39

RNA Precipitation
Following centrifugation, the mixture separated into a lower red, phenol-chloroform
phase, an interphase, and a colorless upper aqueous phase. The aqueous phase containing
the RNA was transferred to a fresh tube.
RNA was precipitated from the aqueous phase by mixing with isopropyl alcohol. For this
0.5 mL of isopropyl alcohol per 1 mL of TRIZOL Reagent was added to the tubes. The
samples were incubated at 15 to 30°C for 10 minutes and then centrifuged at 12,000 x g
for 10 minutes at 2 to 8°C. The RNA precipitated and formed a pellet on the side and
bottom of the tube.
RNA Wash
The supernatant was removed and the RNA pellet was washed once with 1ml of 75%
ethanol per 1 mL of TRIZOL Reagent. The samples were mixed by vortexing and then
centrifuged at 7,500 x g for 5 minutes at 2to 8°C.
Redissolving the RNA
RNA pellet was air dried for not more than 2 minutes before dissolving the RNA in
RNase-free water by passing the solution a few times through a pipette tip, and then
incubating for 10 minutes at 55 to 60°C. The dissolved RNA sample was stored at -80°C
for further use.
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Chapter 3
RESULTS
For all our experiments, we used C.elegans that were treated with 1mM
Amphetamine solution. For this, we first made sure that all the worms were grown
synchronously by starving the worms at L1 larval phase. The starvation ensures that the
worms will all enter the dauer larva stage. After the worms are in the dauer larval stage,
the worms were introduced to bacteria for feeding and this synchronization procedure
results in all of the worms bring in the same growth phase for the duration of the
experiment. After this, the worms were allowed to grow to adult stage. Then adult worms
were collected by washing the plates with M9 buffer, and then the eggs were collected.
Half of the eggs were treated with M9 and the other half were treated with 1mM
amphetamine solution and the worms were then allowed to grow for 15-16 hours till they
reached L4 larval stage when they were collected and the effects of amphetamine
exposure were studied.
Protein Expression of Histone Modifications
The primary goal of this study was to investigate whether exposure to
amphetamine induces changes in histone modifications at the promoters of key genes
within the dopaminergic pathway. First, however, we wanted to investigate whether there
were any global changes in the protein expression levels of the histone modifications that
will be investigated in this study (H3K4me3, H3K27me3 and H3K36me3). In order to
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achieve this, the worms were treated with either 1mM Amphetamine or with vehicle
control for 15 hours. Protein lysates were isolated and western blot analysis performed.
The blots were probed for anti-H3K4me3, anti-H3K36me3 and anti-H3K27me3 and for
anti-Histone H3 as a loading control.
In Figure 5A, the blot intensity of the western blot analysis shows that there was
no change in the expression levels of H3K4me3 in amphetamine treated samples
compared to vehicle control.
In figure 5B, the blot intensity of the western blot analysis shows that there is a
statistically significant increase in the protein expression levels of H3K27me3 in the
amphetamine treated samples compared to the control samples.
Figure 5C shows that there is a statistically significant increase in the protein
levels of H3K36me3 in amphetamine treated samples as compared to control samples.

42

Figure 5: Protein Expression of H3K4me3, H3K27me3 and H3K36me3 in control
and Amphetamine treated samples. The worms were exposed to vehicle control or
1mM amphetamine for 15 hours and then Western blot analysis was performed. Briefly,
the worm samples were boiled in 1X PBS containing 2X Laemmli Buffer and DTT. The
samples were sonicated and electrophoresed on a 4-20% SDS polyacrylamide gel. The
resultant blot intensity was normalized to Histone H3 and are shown as a relative protein
expression ± SD (n=3). Statistical analysis was performed using Student’s unpaired ttest, with statistical significance set at p < 0.05.
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Amphetamine administration induces changes in the global expression of histone
modifying enzymes.
Our western blot analysis revealed the fact that amphetamine induces changes in
the global enrichment of the histone modifications H3K4me3, H3K27me3 and
H3K36me3. In order to confirm our findings and determine whether this was due to
changes in the expression of known histone modifying enzymes, we wanted to
investigate the mRNA expression of these known corresponding histone modifying
enzymes. Histone lysine methyltransferases and histone demthylases are responsible for
the addition or removal of methyl groups at the specific amino acid in a histone protein,
respectively. By adding and removing methyl groups, the histone modifying enzymes
may affect the expression of a gene. We used quantitative real time PCR to look at the
mRNA expression of MET-1, MES-2 and SET-16 histone methyl transferases and UTX1, JMJD-2, RBR-2 histone demethylases in amphetamine treated samples. We found that
there was a statistically significant decrease in the expression of H3K4me3 histone
demethylase RBR-2 in amphetamine treated samples but there was no change in the
expression of H3K4me3 histone methyltransferase SET-16 compared to control smaples
(Figure 6A). The mRNA analysis of H3K27me3 histone methyltransferase MES-2
revealed a significant decrease in MES-2 expression in amphetamine treated samples
compared to control, but the histone demethylase UTX-1 was also decreased (Figure 6B).
There was no change in the expression of H3K36me3 histone methyl transferase MET-1,
but rather, there was a significant decrease in the expression of the histone demethylase
JMJD-2 (Figure 6C). The above data suggests that amphetamine treatment induces
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changes in the expression of histone modifying enzymes which in turn affects the
expression of histone modifications.
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Figure 6: Amphetamine treatment induces changes in the expression of histone
methyltransferases and histone demethylases. The effect of amphetamine treatment
on the expression of the histone modifying proteins was determined by quantitative realtime PCR using cDNA prepared from the transcriptome of wild type and amphetamine
treated worms. Figure shows fold change of SET-16 and RBR-2 (5A), MES-2 and UTX1 (5B), MET-1 and JMJD-2 (5C) over wild type control. All data was normalized to
actin-1 and are shown as a relative fold change ± SD (n=3). Statistical analysis was
performed using Student’s unpaired t-test, with statistical significance set at p < 0.05.
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Enrichment of histone modifications tri-methylated H3K4, H3K27 and H3K36
around the transcription start sites of dopaminergic pathway genes.
Epigenetic modifications have been previously shown to be affected by chronic
exposure to addictive drugs. Rental et al. (43) has recently shown that chronic cocaine
administration can induce changes in the acetylation of Histone H3/H4 at the promoters
of significant number of genes. Histone lysine methylation has long been associated with
either gene activation or gene repression by affecting the transcriptional machinery. Since
our previous finding suggested that acute administration of amphetamine induces changes
in histone modifications at the global level, we wanted to assess if acute amphetamine
administration is able to induce changes in histone modifications at the promoters of the
genes of the dopaminergic pathway. For this, the enrichment of tri-methylated H3K4,
H3K27 and H3K36 around the promoters of bas-1, cat-1, cat-2, dat-1 and dop-2 genes
was measured using chromatin immunoprecipitation (ChIP). Four different primer sets
were prepared for each of these genes, spanning different genomic stretches between 750 base pairs and +250 base pairs (Table 1).
Amphetamine treatment produced no change in the enrichment of H3K4me3,
H3K27me3 and H3K36me3 in bas-1 gene compared to the control (Figure 7A). There
was a statistically significant decrease in the enrichment of H3K4me3 in amphetamine
treated samples in cat-1 gene, but there was no change in the enrichment levels of
H3K27me3 and H3K36me3 (Figure 7B). In cat-2 gene, there was a statistically
significant decrease in the enrichment levels of H3K4me3 and H3K36me3, but there was
no change in the enrichment of H3K27me3 (Figure 7C). At the dat-1gene promoter, there
was statistically significant decrease in the enrichment of H3K4me3 but there was no
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change in the enrichment of H3K27me3 and H3K36me3 (Figure 7D). Amphetamine
induced a decrease in the enrichment of H3K4me3, H3K27me3 and H3K36me3 at the
cat-2 gene promoter (Figure 7E). These data suggest that amphetamine treatment alters
histone modifications at the promoters of genes involved in the dopaminergic pathway,
and that these changes which may potentially influence the mode of action of
amphetamine by increasing the efflux of the catecholamine dopamine in the synapses.
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Table 1: Nucleotide sequence of the primers used in the chromatin
immunoprecipitation analysis. Table listing the nucleotide sequence of the primers used
in the chromatin immunoprecipitation analysis. During the preparation of these primer
sets, we used the nematode genome browser of the University of California, Santa Cruz
at http://genome.ucsc.edu/cgi-bin/hgGateway; the December 2011 assembly. To
calculate the properties of the primers (length, melting temperature, and GC content), we
used the online oligonucleotide properties calculator available at
http://www.basic.northwestern.edu/biotools/oligocalc.html. For each gene, we designed 2
primer sets spanning genomic sequences upstream to the transcription start site (up to 500
base pairs), 1 primer set spanning genomic sequences downstream to the transcription
start site (up to 250 base pairs) and one primer set spanning the transcription start site.
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Gene

Primer
set

Sequence

Forward

TTC CCA AAT CTT TTC
CTG TCC TTT

Reverse

TTC TTT TTC TAC ATT
TAT CCG AGC TA

26

60.1

Forward

TAT CCA CCG CAC CGT
AGT CT

20

60.5

Reverse

TAG ATG TGG TGG CAT
GTC GAA T

22

60.1

Forward

TTC GGT TTT TTT GTT
CTG ACA AGA AA

26

60.1

Reverse

TCG AGT AAA CCG TAG
CGG GA

20

60.5

Forward

TTG CCC GAC TCT TAT
TTA TCT GTA

26

60.3

Reverse

ACC GCT ATT GTA TCA
TAT TCT TTG TT

Primer
set #1

dat1

Primer
set #2

60.3

146bp

153bp

Primer
set #4

154bp

Primer
set

Sequence

26

60.1

Melting
Length temperature
(°C)

Forward

TAA AAT TTC TCT ATC
TAT TCC GGG AA

Reverse

AGG GTG AAC ACT GGT
AAT GAC A

22

60.1

Forward

TTC CTT TTT TTC GCG
GAC TCC A

22

60.1

Reverse

TAG ATT CCC ACG GTC
TGA AAA ATT

24

60.3

Forward

TCA GTT TTG TTA TCA
CAT TTC TCA CA

26

60.1

Reverse

AAA GTA GAA TTT TCC
TAT TGT TCC GA

26

60.1

Forward

ACA GTT GGT AAG TTT
CTG GAA ACA

21

60.3

Reverse

TTT TGA GAG TTG TGA
CTG AAC AGA

Primer
set #1

cat1

23

Amplic
on size
(bp)

127bp

Primer
set #3

Gene

Melting
Length temperature
(°C)

26

Amplic
on size
(bp)

60.1
85bp

Primer
set #2

151bp

Primer
set #3

148bp

Primer
set #4

136bp

54

24

60.3

Table 1 Continued
Gene

Primer
set

Sequence

Forward

TTC ATA TGC TGG GTT
ATC AGT TCT

Reverse

ACG TTC ACC GCC GCA
ATT AG

20

60.5

Forward

TCG TCA CTA ACC AAC
AAT ACT TTC A

25

60.9

Reverse

AGG TTC TTC CTC CTA
GAA ATT GAA A

25

60.9

Forward

TGG TGC ACC AAG CGA
GTT GT

20

60.5

Reverse

ACA AGA GCT TGT ATG
GAT TAC TGT A

25

60.9

Forward

TTC CGA CGA TTC AGA
TTC TCC A

22

60.1

Reverse

TTG GGT CAG TGG AAG
TGA GAA T

Primer
set #1

cat2

Primer
set #2

60.3

176bp

130bp

Primer
set #4

114bp

Primer
set

Sequence

22

60.1

Melting
Length temperature
(°C)

Forward

GCT TAA TGT GTG CTT
TGT GTT AGA

Reverse

TTC TTT ACC AAT GCT
CAG ATG ACT

24

60.3

Forward

AGA TTC TTT CTG TTA
TCG AGT CTA AA

26

60.1

Reverse

AAC GTA ATA GAT TTT
AGT TTC TCA GA

26

58.4

Forward

ACA CCT TTG TTT TTA
CCT TCT TCA A

25

59.2

Reverse

AAG AGA GGG TGG AGG
CCA TT

20

60.5

Forward

TGA ACT ACG CTG GAC
TTT CTC T

22

60.1

Reverse

ATT TTT TAA CTG ACA
ATT GAA CTC TAA C

Primer
set #1

dop2

24

Amplic
on size
(bp)

118bp

Primer
set #3

Gene

Melting
Length temperature
(°C)

24

Amplic
on size
(bp)

60.3
139bp

Primer
set #2

112bp

Primer
set #3

141bp

Primer
set #4

94bp

55

28

59.9

Table 1 Continued
Gene

Primer
set

Sequence

Forward

TGC CGA CGC TCA TCA
TCA CT

Reverse

TGT CAA AAG TTC TGA
AAA CGG AAA TA

26

60.1

Forward

TTT CTG CAG CCA ATT
CTT TTT CTC

24

60.3

Reverse

ATA CCT ATC CAT CTA
TGC GCG A

22

60.1

Forward

TCC CCT CAT TTC TCT
TAT TTT CCT

24

60.3

Reverse

AGT AGT CCG CCA CAA
AAT CCA

21

59.5

Forward

ACC ACT GCC TGA TGT
TAA ACC A

22

60.1

Reverse

TCG GCT CGT GGC CTA
GTA AA

Primer
set #1

bas1

Melting
Length temperature
(°C)
20

Amplic
on size
(bp)

60.5
193 bp

Primer
set #2

154bp

Primer
set #3

171bp

Primer
set #4

133bp

56

20

60.5

Figure 7: Enrichment of tri-methylated H3K4, H3K27 and H3K36 around the
transcription start sites of dopaminergic pathway genes in control and amphetamine
treated worms. Figure shows the fold changes in the levels of enrichment of trimethylated H3K4, H3K27 and H3K36 at bas-1 (A), cat-1 (B), cat-2 (C), dat-1 (D), and
dop-2 (E) genes measured by chromatin immunoprecipitation analysis followed by qrtPCR, in C.elegans treated with 100mM amphetamine for 15 hours, with water as control.
The cartoon in the bottom shows the possible Transcription Factor binding sites based on
sequence specificity calculated from http://www.Cbrc.jp/research/db/ TFSEARCH.html
Bars represent means + SD (n=3) where statistical analysis was performed using
Student’s unpaired t-test, with statistical significance set at p < 0.05.
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Amphetamine treatment induces changes in the expression of genes in the
dopaminergic pathway.
We addressed the question of whether acute amphetamine treatment alters gene
expression in the dopaminergic pathway. Using qrt-PCR, we looked at the effect of
amphetamine on individual genes of the dopamine signaling pathway which included
bas-1, cat-1, cat-2, dat-1, dop-1 and dop-2. Our qrt-PCR analysis revealed that
amphetamine treatment decreases the expression of bas-1, cat-1, dat-1, dop-1 and dop-2,
but increases the expression of the cat-2 gene which encodes the protein tyrosine
hydroxylase (Figure 8). These results support the findings that amphetamine treatment
alters the expression of the genes involved in the dopaminergic pathway, an effect that
might help shed light onto complex mechanism of action by which of amphetamine
induces efflux of cellular dopamine in the synapses.
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Figure 8: Amphetamine treatment induces changes in the expression of genes in the
dopaminergic pathway. The effect of amphetamine treatment on the expression of the
genes of the dopaminergic pathway was determined by quantitative real-time PCR using
cDNA prepared from the transcriptome of wild type and amphetamine treated worms.
Figure shows fold change of individual genes over wild type control. Data was
normalized to actin-1.
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Chapter 4
DISCUSSION
Epigenetic modifications, which include histone modifications like acetylation,
phosphorylation and methylation, have been known to play important roles in the
development and the differentiation of an organism. Epigenetic modifications are also
known to be affected by environmental stimuli such as heavy metals and pesticides. Zhou
et al. showed that arsenic disrupts epigenetic events by altering histone modifications
(52). Addictive drugs have also been known to induce changes in the epigenetic

modifications. Recent study by Renthal et al. revealed that cocaine treatment induces
changes in the acetylation states of H3/ H4 (49), an effect that was associated with the
sirtuin family of proteins.
The main goal of this study was to determine if exposure to amphetamine is able
to induce changes in histone modifications at the promoters of the key genes of the
dopaminergic pathway. Our western blot analysis shows that there is a significant
increase in the expression of H3K27me3 and H3K36me3 at the global level in
amphetamine treated samples.
This suggests that there is an increase in the protein expression of H3K27me3 and
H3K36me3 at the global level in amphetamine treated samples compared to control
samples. Trimethylation of lysine 27 on histone 3 (H3K27me3) is a mark that is known to
be associated with the repression of transcription in a cell type specific manner. A global
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increase in the protein expression levels of H3K27me3 may be associated with an
increase in the formation of heterochromatin, which is characteristic of transcriptionally
silent chromatin.
Trimethylation of lysine 36 on Histone 3 (H3K36me3) is considered as a marker
of transcriptional elongation, as this mark is mainly co-enriched with the Ser2phosphorylated elongating form of RNA polymerase (Pol) II at the coding region (CR) of
the gene body. Therefore, a global increase in the protein expression of H3K36me3 is
associated with increased transcription status.
Although the western blot analysis revealed that there was a change in expression
levels of H3K27me3 and H3K36me3 at the global level, this observation does not
necessarily correlate with the fact that there will be a similar observation at the gene level
for the genes of interest in this study. This may be because histone post translational
modification is a dynamic process; it undergoes dynamic changes at various stages of
life. For example, Lander et al. have shown that methylation of CpGs undergo extensive
changes during cellular differentiation. Moreover, histone methylation patterns are
correlated with DNA methylation patterns (53). This suggests that histone methylation is
a dynamic process and may vary across the genome. The western blot analysis revealed
several important pieces of information. First, exposure to amphetamine disturbs the
epigenetic pattern in a way that it brings about changes in the global levels of these
covalent modifications. This supports our hypothesis so far that exposure to amphetamine
may induce changes in histone modifications at the promoter region of genes.
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In order to further study the changes in the histone modifications by amphetamine, we
looked at the protein levels of the various histone modifying enzymes using mRNA
expression. Our mRNA expression study showed that exposure to amphetamine leads to
a statistically significant decrease in the levels of H3K4me3 histone demethylase RBR-2
and H3K36me3 histone demethylase JMJD-2, but that there was no change in the
expression levels of the histone methyltransferases of the above mentioned modifications
from wild type worms. Although there was a statistically significant increase in the
expression of H3K27me3 in our western blot analysis, the protein levels the histone
methyltransferase MES-2 and histone demethylase UTX-1 were both found to be
decreased in amphetamine treated samples compared to the control samples. This
suggests that the H3K27me3 mark might have a lesser role in the regulation of gene
expression in amphetamine treated samples or as the worms develop, although further
work is warranted to confirm this. These results indicate that amphetamine treatment
increases the expression of H3K4me3 and H3K36me3 modifications by reducing the
protein levels of the histone demethylases.
The next phase of the study was to examine whether exposure to amphetamine induces
changes in histone modifications in the promoter region of the genes of the dopaminergic
pathway. Amphetamine has been known to exert its behavioral effect primarily by
increasing the extracellular levels of dopamine. This effect is thought to be elicited by the
reversal of the dopamine transporter (DAT) and thereby modification of dopamine
signaling (5). The dopamine signaling pathway consists of tyrosine hydroxylase cat-1,
aromatic amino acid decarboxylase bas-1, vesicular monoamine transporter cat-2,
dopamine transporter dat-1 and dopamine receptors dop-1 and dop-2. We wanted to
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examine if amphetamine exerts its effects by manipulating various histone modifications
at these key gene promoters. For, this we measured the enrichment of H3K4me3,
H3K27me3 and H3K36me3 at the promoter regions of the genes of the dopaminergic
pathway using chromatin immunoprecipitation (ChIP). We find that amphetamine
treatment has no effect on the amino acid decarboxylase bas-1 (Figure 7A). Chromatin
immunoprecipitation analysis of cat-1 reveals that amphetamine treatment significantly
decreases the enrichment of tri-methylated H3K4me3, but there was no change in the
enrichment of H3K27me3 and H3K36me3 (Figure 7A). cat-1 encodes for vesicular
monoamine transporter which packages cellular dopamine from the cytoplasm into
specialized vesicles, by an active transport mechanism and stores dopamine until it is
released by exocytosis into the synapses. This result implies that amphetamine reduces
the expression of VMAT, which might indicate the increased cytoplasmic dopamine
levels. Previous studies have shown that amphetamine affects vesicle storage of
dopamine in synaptic vesicles by reducing the ability of VMAT to store the
neurotransmitter, possibly by synaptic vesicle localization (15, 54) which suggests that
amphetamine treatment might induce changes in the expression of the vesicular
monoamine transporter by introducing changes in the histone modifications in the
promoter region such that the protein expression is altered. We find that amphetamine
treatment significantly decreases the enrichment of both H3K4me3 and H3K27me3,
while increasing expression of tyrosine hydroxylase cat-2 gene (Figure 7C). This may be
partially explained by the fact that we find that although there is a significant decrease in
the H3K4me3 enrichment in primer set 4, we find a greater decrease in the enrichment of
H3K27me3 in primer set 4. The primer set 4 is located closer to the transcription start
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site, and as we can see in Figure 4A, the H3K4me3 and H3K27me3 marks are highly
enriched around the transcription start site. This suggests that the greater reduction in the
enrichment of H3K27me3 compared to the H3K4me3 may be the primary regulatory
factor in terms of gene activation at this promoter. Since, cat-2 encodes the tyrosine
hydroxylase gene, this suggests that amphetamine increases the expression of tyrosine
hydroxylase, which then increases the synthesis of dopamine. We hypothesize that since
we have seen earlier that amphetamine decreases the expression of VMAT, and that this
suggests that as there is an increase in the synthesis of dopamine, the VMAT may not be
able to efficiently package the excess dopamine, thereby increasing the concentration of
cytosolic dopamine. This may then be funneled out to the pre-synaptic space through the
dopamine transporter. The enrichment of H3K4me3 in dat-1 (Figure 7D) shows a
statistically significant decrease in primer set 2 and 3 which suggests that there might be
a reduction in the enrichment of H3K4me3. We find no change in the enrichment of
H3K27me3 and H3K36me3, and this might indicate a reduction in the expression of
dopamine transporter. Recent work by Carvelli et al. has indicated that DAT plays an
important role in the ability of amphetamine to increase extracellular dopamine (5). We
suggest that this decrease in the expression of dat-1 leads to increased concentration of
extracellular dopamine as the lower expression of DAT prevents the shuttling of
extracellular dopamine inside the neuron, which is a manifestation of the action of
amphetamine. Recent work by German et al. has showed that in vivo amphetamine
treatment decreases DAT function (55). dop-2 shows reduced enrichment of H3K4me3,
H3K27me3 and H3K36me3 (Figure 7E). This might suggest a reduced expression of the
type II dopaminergic neurons.
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Our next goal was to confirm our observations in the chromatin Immunoprecipitation.
For this we wanted to see the mRNA expression of the genes of the dopaminergic
pathway. We looked at the transcriptional levels of the various components of the
dopaminergic pathway using mRNA expression (Figure 8). Our mRNA expression study
showed that exposure to amphetamine lead to decrease in the expression of dat-1, cat-1,
bas-1, dop-1 and dop-2 but there was an increase in the expression of cat-2 which
encodes tyrosine hydroxylase. This is largely in agreement with our chromatin
immunoprecipitation reaction observations.
To our knowledge, no studies have been done to date on the role of amphetamine
in inducing changes in histone modifications at the promoter region of the genes of the
dopaminergic pathway. Our results show that amphetamine treatment induces changes in
the expression of the dopaminergic pathway genes by controlling various histone
modifications at the promoter region of these genes. We find that amphetamine brings
about its manifestation of increasing extracellular/synaptic dopamine by the down
regulation of vesicular monoamine transporter, which becomes unable to package
dopamine, thereby increasing the concentration of cellular dopamine. This increase in
cellular dopamine may be exported out of the neurons by action of amphetamine on the
reverse transport of the dopamine transporter. The main role of the dopamine transporter
is to pump back extra dopamine that has net been picked up by the dopaminergic
receptors in the post-synaptic neurons, and restore dopamine levels in the pre-synaptic
neuron. Amphetamine also seems to down regulate the dopamine transporter, which
suggests that the function of the dopamine transporter is affected in a way that the ability
of DAT to funnel synaptic dopamine is hampered. Finally we say that as this study was
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performed on Caenorhabditis elegans, further analysis is necessary in order to correlate
the data with clinical outcomes.
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